MedTrace Logo

Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients

NCT00273741 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2009-12-07

No results posted yet for this study

Summary

The aim/objective of this study is to evaluate the antiasthenic effect of methylphenidate with a visual analogical scale (VAS) after 7 days of treatment, in cancer patients, in palliative care, i.e. with a progressive or terminal disease.

Conditions

  • Asthenia
  • Neoplasms

Interventions

DRUG

methylphenidate

methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days

DRUG

placebo comparator

placebo capsules

Sponsors & Collaborators

  • Fondation de France

    collaborator OTHER

  • Ligue contre le cancer, France

    collaborator OTHER

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Guillemette Laval, M.D., Ph.D. · University Hospital, Grenoble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00273741 on ClinicalTrials.gov